Drugs developed by Alphabet’s drug discovery subsidiary and designed by artificial intelligence are expected to head to trial by the end of the year, according to a Google (GOOGL) executive.

With zero-click results and skyrocketing referral traffic, LLMs are the new gatekeepers of the web. Adapt your strategy for this shift.

Google challenges OpenAI with free Gemini 2.0 Flash Thinking model, offering million-token processing, native code execution, and breakthrough performance in math and science benchmarks.

With "Mind Evolution" LLMs can use search and genetic algorithms to generate and combine different solutions and find the optimal one.

Jill McVicar Nelson explains what the brand has learned from its Super Bowl ads and how it’s facing uneasiness around ...

A creeping shift has redefined how brands maintain identity over recent years, chasing audiences as they jump between endless ...

Francis deSouza is Google Cloud’s new chief operating officer. He co-founded AI research startup Synth Labs last year after ...

As it looks to accelerate the pace of its AI development, Google is further streamlining the teams building its AI services, platforms, and tools. On Thursday, Logan Kilpatrick, who leads product for ...

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Seth Berkman Seth Berkman is a writer covering fitness. He's showered ...

I've personally tested well over 160 audio products since becoming a full-time audio writer in 2019, but TechRadar's been in this game since 2006, with the wider TechRadar team clocking in over ...

Zarrin Ahmed is a Deals and Commerce writer at CNET. She loves helping people find great deals on products they can't live without, things they want, and things they never knew they needed.

Google's folding of dev-focused AI teams into its Google DeepMind org comes after the company moved the team behind its Gemini-powered chatbot, also called Gemini, to DeepMind.